Improved sales expectations for Skyrizi and Rinvoq and acquisitions in oncology and neuroscience add confidence AbbVie can continue growing.I now see EPS growing at 8.2% per year through 2030, faster ...
Source LinkImproved sales expectations for Skyrizi and Rinvoq and acquisitions in oncology and neuroscience add confidence AbbVie can continue growing.I now see EPS growing at 8.2% per year through 2030, faster ...
Source Link
Comments